CryoPort (NASDAQ:CYRX) Director Ramkumar Mandalam Sells 23,214 Shares

CryoPort, Inc. (NASDAQ:CYRX) Director Ramkumar Mandalam sold 23,214 shares of the business’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $15.44, for a total transaction of $358,424.16. Following the completion of the transaction, the director owned 67,894 shares of the company’s stock, valued at approximately $1,048,283.36. This represents a 25.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

CryoPort Stock Performance

Shares of CYRX traded down $0.22 during trading hours on Monday, hitting $15.48. The stock had a trading volume of 573,254 shares, compared to its average volume of 912,079. The firm has a 50-day moving average price of $11.89 and a 200 day moving average price of $10.17. CryoPort, Inc. has a fifty-two week low of $6.16 and a fifty-two week high of $16.73. The firm has a market capitalization of $780.19 million, a price-to-earnings ratio of 11.47 and a beta of 1.90.

CryoPort (NASDAQ:CYRX) last posted its earnings results on Monday, May 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). CryoPort had a net margin of 41.57% and a negative return on equity of 7.92%. The firm had revenue of $47.80 million during the quarter, compared to analyst estimates of $44.86 million. As a group, analysts predict that CryoPort, Inc. will post -0.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on CYRX shares. Needham & Company LLC boosted their price target on shares of CryoPort from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Wall Street Zen raised shares of CryoPort from a “sell” rating to a “hold” rating in a report on Monday, May 11th. BTIG Research boosted their price target on shares of CryoPort from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Jefferies Financial Group set a $13.50 price target on shares of CryoPort in a report on Monday. Finally, KeyCorp boosted their price target on shares of CryoPort from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Wednesday, May 20th. Eight equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, CryoPort currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.11.

Institutional Investors Weigh In On CryoPort

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. LPL Financial LLC raised its holdings in CryoPort by 6.6% in the fourth quarter. LPL Financial LLC now owns 23,306 shares of the company’s stock valued at $224,000 after acquiring an additional 1,433 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in CryoPort by 9.4% in the second quarter. The Manufacturers Life Insurance Company now owns 18,178 shares of the company’s stock valued at $136,000 after acquiring an additional 1,557 shares in the last quarter. State of Wyoming raised its holdings in CryoPort by 30.2% in the second quarter. State of Wyoming now owns 14,218 shares of the company’s stock valued at $106,000 after acquiring an additional 3,301 shares in the last quarter. Basepoint Wealth LLC acquired a new stake in CryoPort in the fourth quarter valued at approximately $34,000. Finally, BNP Paribas Financial Markets raised its holdings in CryoPort by 55.2% in the third quarter. BNP Paribas Financial Markets now owns 11,880 shares of the company’s stock valued at $113,000 after acquiring an additional 4,225 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.